|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 48, 46151-46158, November 29, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Immunology, Duke University Medical Center,
Durham, North Carolina 27710
Received for publication, September 3, 2002
Membrane-associated adaptors play an important
role in coupling antigen receptor engagement to downstream signaling
events, such as Ras-MAPK activation, Ca2+ flux, and
nuclear factor of activated T cells (NFAT) activation. Here we
identified a novel membrane-associated adaptor protein, LAX. LAX is
mainly expressed in B cells, T cells, and other lymphoid-specific cell
types. It shares no overall sequence homology with LAT and is not
localized to lipid rafts. However, like LAT, LAX has tyrosine motifs
for binding Grb2, Gads, and the p85 subunit of phosphatidylinositol 3-kinase. Upon stimulation via the B or T cell receptors, LAX is
rapidly phosphorylated by Src and Syk family tyrosine kinases and
interacts with Grb2, Gads, and p85. Overexpression of LAX in Jurkat
cells specifically inhibits T cell receptor-mediated p38 MAPK
activation and NFAT/AP-1 transcriptional activation. Our data suggested
that LAX functions to negatively regulate signaling in lymphocytes.
Recognition of antigens by antigen receptors, the B cell receptor
(BCR)1 and the T cell
receptor (TCR), initiates a series of biochemical events involving a
variety of distinct signaling pathways that eventually lead to gene
transcription, clonal expansion, and cellular differentiation. Although
the BCR and TCR have different structures and recognize different forms
of antigens, signaling pathways activated via these two receptors are
strikingly similar. Both the BCR and TCR utilize receptor-encoded
signaling motifs termed ITAMs (immunoreceptor tyrosine-based activation
motifs) to activate non-receptor tyrosine kinases (1). Following
receptor engagement, Src family tyrosine kinases, activated by the CD45
phosphatase, phosphorylate the paired tyrosine residues within ITAMs.
Syk family kinases are then recruited to the receptor by binding
phosphorylated ITAMs via their tandem SH2 domains and are subsequently
activated by Src family kinases (2). These activated tyrosine kinases further phosphorylate multiple cellular proteins, including enzymes and
adaptor proteins (3-8), leading to activation of the Ras-MAPK pathway
and Ca2+ flux.
Several studies using deficient cell lines have shown that adaptor
proteins are essential for lymphocyte activation by coupling receptor
engagement to activation of the Ras-MAPK pathway, Ca2+
mobilization, and cytokine production (9-11). In T cells, LAT and
SLP-76 have been intensively studied in recent years (6, 12-15). LAT
is a membrane-associated adaptor protein. Upon phosphorylation, LAT
interacts with Grb2, Gads, and PLC- As a membrane-associated adaptor protein, LAT plays a critical role in
signaling in T cells. Similar molecules might also exist in other cell
types with immune receptors. A similar molecule has not been found in B
cells. It has been proposed that BLNK functions as both LAT and SLP-76
to link the BCR engagement to MAPK activation and Ca2+ flux
(23). BCR-induced PLC- To look for a LAT-like molecule in B cells and other cell types, we
searched the human genome data base with the tyrosine motifs in LAT and
identified a novel gene. We named it LAX. Like LAT,
LAX is a membrane-associated adaptor protein. It is expressed in T
cells, B cells, and other cell types of lymphoid origin. It associates
with Grb2, Gads, and the p85 subunit of PI-3 kinase. However, it is
unlikely that LAX functions as a B cell LAT-like molecule.
Our data show that as opposed to LAT, LAX functions to negatively
regulate antigen-receptor signaling in T cells by inhibiting
TCR-mediated p38 MAPK activation.
Molecular Cloning of LAX--
The LAT peptide sequence from
residues 160-180, which contains an important tyrosine
(Tyr-171) in LAT function, was used to search the human genome
data base in NCBI using the BLAST program to identify molecules similar
to LAT. We looked for novel transmembrane proteins that contain
tyrosine motifs similar to those in LAT. A hypothetical protein
FLJ20340 (GenBankTM accession number XP_001752) was
identified as a potential candidate. The nucleotide sequence of this
protein was then used to search the human EST data bases to find
corresponding EST clones. Based on the nucleotide sequence of merged
EST clones, we designed two primers (5'- CACGAGATAGGGAGTTTGTTGCGGG-3'
and 5'-GGCAGTTAGCACATTTTCATAGTCAC-3') to amplify cDNAs from Jurkat
cells with Pfu DNA polymerase. The PCR product was cloned
into pBluescript (KS+) and sequenced by automated sequencing. The mouse
LAX sequence was obtained by BLAST searching a mouse EST
data base using the human LAX sequence. The mouse
LAX cDNA was cloned using primers
(5'CTTCAGTTGGCCTGAGAGCTAACAGC-3' and
5'-CCCCTCAGAGGTCCAGTGATGTACAG-3') to amplify the cDNA from the mouse spleen. The GenBankTM accession number for human
LAX is AY090784 and the accession number for mouse
LAX is AY090785.
Tissue Expression of LAX--
Detection of LAX
expression in different human tissues was done by RT-PCR using primers
(5'-TTTCAGTACTGAGAGCCTCCTCTCCAGA-3' and
5'-GGCAAGATGTCATAAATATTTTTGGCTC-3'). cDNAs from different human
tissues were purchased from Clontech and used in
PCRs. cDNAs from different human cell lines were obtained by
reverse transcription with total RNAs. G3PDH primers
(5'-TGAAGGTCGGAGTCAACGGATTTGGT-3' and 5'-CATGTGGGCCATGAGGTCCACCAC-3')
were included in the PCR as a control. The PCR for amplification
of LAX was done using the following condition: 94 °C for
30 s, 55 °C for 1 min, and 72 °C for 1 min for 35 cycles.
PCR products were resolved on a 1.5% agarose gel.
Constructs--
A Myc epitope tag was added to the C terminus of
LAX by PCR. The Myc-tagged LAX cDNA was then cloned into
the expression vector pLXIN (Clontech) for
generating stable cell lines and the pCEFL vector for transient
transfection. Mutation of tyrosine residues was performed using the
Stratagene QuickExchange kit. The GST-LAX fusion construct was made by
cloning the ScaI/NotI fragment of human
LAX into the SmaI/NotI sites of
pGEX4T-2.
Antibodies--
Rabbit anti-LAX antisera were obtained by
immunization of rabbits with GST-LAX fusion proteins. Anti-human LAX
monoclonal antibodies were made by fusion of splenocytes from mice
immunized with GST-LAX with NSO cells. Other antibodies used in this
study are as follows: rabbit anti-LAT (26), anti-Grb2 antisera from Santa Cruz Biotechnology; rabbit anti-p85 antisera, rabbit anti-Gads antisera, anti-phosphotyrosine, and anti-PLC Immunoprecipitation and Cell Fractionation--
Jurkat and Daudi
cells were cultured in RPMI 1640 with 10% fetal bovine serum. Before
stimulation, cells were removed from the culture, washed, and
resuspended at 108 cells/ml in RPMI 1640. Cells were
stimulated with anti-TCR Stable Transfection, Ca2+ Flux, and MAPK
Activation--
Jurkat cells were transfected with 5-10 µg of
LAX-WT or LAX-4YF pCEFL plasmid by electroporation using a BTX
electroporator (310 V, 10 ms). Stable transfectants were selected in
the media containing G418 and further subcloned by limiting dilution.
Clones expressing similar levels of CD3, CD28, and LAX were selected and used for further experiments. Intracellular free Ca2+
measurement was performed as described previously (28). For MAPK
activation, Jurkat cells and three transfectant clones, which expressed
either LAX-WT or LAX-4YF, were stimulated with C305 plus anti-CD28 for
0, 5, 10, and 15 min. Equal volume of 2× SDS sample buffer were added
to stop the stimulation, and samples were resolved on SDS-PAGE.
Activation of p38, Erk, and JNK were detected by blotting the membranes
with different antibodies.
Transfection and Luciferase Assay--
For luciferase assays,
1 × 107 Jurkat cells (E6.1 or LAT deficient ANJ3)
were transfected with 5 µg of pNFAT/AP-1-luciferase or
AP-1-luciferase plasmids, 20 ng of Renilla-TK
luciferase plasmid, and LAT or different amounts of LAX plasmids by
electroporation using a BTX electroporator (310 V, 10 ms). Sixteen to
twenty four hours after transfection, cells were stimulated with OKT3
(1:500 ascites), PMA (10 ng/ml) plus ionomycin (1.5 µM),
or left untreated for 6 h. Dual luciferase activity was assayed
according manufacturer's protocol (Promega). NFAT-luciferase activity
was normalized by Renilla-TK activity.
Cloning of LAX--
To look for proteins that are homologous to
LAT, we performed an extensive search of the NCBI data base using the
entire coding sequence of LAT, and we failed to find any LAT homolog in
the data base. Next we used the tyrosine motifs in LAT to search the data base. A LAT-like molecule might have no overall sequence homology
to LAT but may contain similar tyrosine motifs that are responsible for
binding important signaling proteins and are essential in LAT function.
Of the nine conserved tyrosines in the cytoplasmic domain of LAT,
Tyr-171 and Tyr-191 are particularly important. Mutation of these two
tyrosines abolished the association of LAT with Grb2, Gads, and
PLC-
The peptide sequences from residues 160-180 and 181-200 of LAT were
used to search the human genome data base. Of the many candidate
proteins that have a YVNV motif, we identified one candidate for a
LAT-like molecule in the human genome. It is a hypothetical protein
encoded by one large exon in human chromosome 1 (FLJ20340, GenBankTM accession number, XP_001752). This protein
contains a YVNV motif like Tyr-171 and Tyr-191 in LAT and a YVNM motif
that is a potential binding site for Grb2, Gads, and the p85 subunit of
PI-3 kinase. Furthermore, it also contains one YENV and one YENL motif
similar to Tyr-226 (226YENL) in LAT. However, there
is no potential transmembrane domain present in this hypothetical
protein. Because the sequence of this protein was translated from one
single exon in the genome, it is likely to be partial.
To identify the full-length sequence of this protein, we used the
nucleotide sequence of this hypothetical protein to search the human
EST data base, and we found three overlapping EST clones in the data
base. These EST clones were from germinal center B cells, pre-B cells,
and Jurkat T cells. Based on the nucleotide sequence from these EST
clones and the genomic sequence, we designed primers to amplify a
cDNA fragment by Pfu DNA polymerase using cDNAs from
Jurkat cells as template. The amplified cDNA fragment was cloned
into a mammalian expression vector and sequenced. We named this gene,
LAX (Linker for Activation of
X cells, X indicates "to be defined"). Translation of
the human LAX cDNA revealed that the LAX gene
encodes a putative protein of 398 residues (Fig. 1A).
We also used the human LAX sequence to search a mouse EST data base,
and we identified several EST clones from mouse lymph nodes. Based on
the merged sequence of these EST clones, we designed PCR primers and
amplified mouse LAX using cDNA from mouse spleen. Translation of
the mouse LAX cDNA revealed that mouse LAX has 407 residues (Fig.
1A). Comparison of mouse and human LAX proteins showed that
they share 52% identity.
Tyrosine Motifs in LAX--
A pairwise comparison of LAX with LAT
revealed no significant sequence homology. Despite the lack of homology
to LAT in protein sequence, the overall domain organization of LAX was
very similar to that of LAT. LAX has an extracellular domain with ~40
residues, a transmembrane domain consisting of a stretch of hydrophobic residues, and a cytoplasmic domain with multiple tyrosine motifs. Interestingly, there is a cysteine residue near the C-terminal end of
the transmembrane domain. Similar cysteine residues in LAT are
palmitoylated and required for LAT localization to lipid rafts and
tyrosine phosphorylation (27). The cytoplasmic domain of LAX protein
contains many acidic residues (28 Glu and 26 Asp in human LAX) like
LAT. Five of the 10 tyrosines in human LAX are within a Grb2-binding
motif (Tyr-155, Tyr-193, Tyr-268, Tyr-294, and Tyr-373) when
phosphorylated. Of these five Grb2-binding tyrosines, Tyr-193 is within
the sequence context of 193YVNV, which is identical to
Tyr-171 and Tyr-191 in LAT. Interestingly, Tyr-268 is within the
sequence context of 268YVNM. This motif could potentially
bind Grb2, Gads, and the p85 subunit of PI-3 kinase. This
YXXM motif is not present in LAT. In addition, Tyr-294
(294YENV) and Tyr-373 (373YENV) are similar to
Tyr-226 (YENL) in LAT (Fig. 1B).
Tissue-specific Expression of LAX--
Next we determined in which
tissues LAX is expressed. RT-PCR was performed to detect LAX expression
in different human tissues and cell lines. As shown in Fig.
2, a PCR fragment corresponding to the
predicted size was clearly seen when cDNAs from the spleen, thymus,
and peripheral blood leukocytes were used in the PCR
amplification, suggesting that LAX is predominantly expressed in these
tissues. We also used cDNAs from nine different cell lines in PCRs
to detect LAX expression. LAX cDNA was detected in
several B cell lines (BJAB, Daudi, Raji, and Jiyoye), YT (NK-like
cells), THP1 (monocytes), and Jurkat cells (T cells). LAX was not
present in HeLa (fibroblastoid) and K562 cells (myelomonocytic cells).
These results indicated that LAX is predominantly expressed in cells of
hematopoietic origin. In contrast to LAT, LAX is expressed in B cell as
well as T cells and other cell types.
Subcellular Localization of LAX--
To study the function of the
LAX protein biochemically, we made a GST-LAX fusion protein and used it
as an antigen to raise polyclonal antiserum against human LAX. First,
we examined the subcellular localization of LAX by fractionating Jurkat
cells into cytosolic and membrane fractions. The membrane fraction was further solubilized with 1% Brij97 lysis buffer. Because it was difficult to detect LAX by blotting total lysates directly with our
antiserum, LAX protein was immunoprecipitated and resolved on SDS-PAGE.
LAX was then detected by anti-LAX immunoblotting. LAX migrated as a
70-kDa protein on SDS-PAGE under reducing conditions, although the
calculated molecular mass for LAX was only 44 kDa. The
discrepancy is likely due to the presence of more negative charged
residues (29 Asp and 29 Glu) than positive charged residues (12 Lys and
23 Arg) in LAX. As shown in Fig.
3A, LAX was present in the
membrane fraction, not in the cytosolic fraction. We also immunoblotted
lysates from both fractions with anti-LAT and anti-ZAP-70 antibodies as
controls for fractionation. As expected, LAT was found in the membrane
fraction, and ZAP70 was detected in the cytosolic fraction. These
results showed that LAX is constitutively associated with the cell
membrane.
Next we determined whether LAX is partitioned into lipid rafts. The
cysteine residue near the transmembrane domain of LAX could possibly be
palmitoylated to target LAX into lipid rafts. To purify lipid rafts,
Jurkat cells were lysed with 1% Triton lysis buffer, and the resulting
cell lysates were subjected to step sucrose gradient
ultracentrifugation. After centrifugation, 12 fractions from the
sucrose gradient were collected and further analyzed. Most proteins in
the lipid rafts were in fraction 3, and Triton-soluble proteins were in
fractions 8-12. As shown in Fig. 3B, LAX was primarily
detected in fractions 8-12 and not in fraction 3. Conversely, a large
portion of LAT was found in lipid rafts (Fig. 3B,
fraction 3) as reported previously (27). A similar result
was obtained when Daudi B cells were used (not shown). In addition, LAX
was not localized to the raft fractions after T cell or B cell
activation (not shown). These data indicated that different from LAT,
LAX is not localized in lipid rafts although it is present in the membrane.
LAX Is Phosphorylated Upon Antigen Receptor
Stimulation--
Because LAX is expressed in both B and T cells and
contains multiple tyrosine motifs that could potentially bind Grb2 and p85, we examined whether LAX can be phosphorylated upon stimulation via
the BCR or TCR. Jurkat cells were stimulated with an anti-TCR LAX Is a Substrate of Src and Syk Family Tyrosine Kinases--
LAX
is tyrosine-phosphorylated upon stimulation via the TCR or BCR. Next we
identified which tyrosine kinases can phosphorylate LAX. Myc-tagged LAX
was transiently coexpressed with Syk, Lck, or Lck and ZAP-70 in 293T
cells. Myc-tagged LAT was also coexpressed with these tyrosine kinases
as a positive control. 36 h after transfection, LAX or LAT was
immunoprecipitated with an anti-Myc antibody. Phosphorylation of LAT
and LAX was detected by anti-phosphotyrosine blotting. Myc-tagged LAX
migrated on SDS-PAGE as a 70-kDa protein, the same size as the
endogenous LAX, indicating that we have cloned the full-length coding
sequence of LAX. As shown in Fig.
5A, there was no tyrosine
phosphorylation of LAX when it was expressed alone in 293T cells. When
LAX was coexpressed with Syk, Lck, or Lck and ZAP-70, LAX became
tyrosine-phosphorylated, suggesting that LAX is likely a substrate of
these tyrosine kinases. LAT was phosphorylated similarly by these
tyrosine kinases as reported previously (26).
We further examined tyrosine phosphorylation of LAX in two deficient
Jurkat cell lines. P116 is a cell line deficient in ZAP-70 (28) and
J.CaM1.6 is deficient in Lck tyrosine kinase (26). After stimulation of
these cells with an anti-TCR LAX Interacts with Grb2, Gads, and the p85 Subunit of PI-3
Kinase--
The cytoplasmic domain of LAX contains multiple tyrosine
motifs that may interact with Grb2, Gads, and p85. We tested whether LAX can associate with these proteins after T cell activation. Myc-tagged wild-type LAX and a mutant LAX with mutation of four tyrosines (Tyr-193, Tyr-268, Tyr-294, and Tyr-373) were transfected into Jurkat cells, and stable clones were established for further studies. After stimulation of stable transfectants with C305, LAX
protein was immunoprecipitated from lysates and resolved on SDS-PAGE,
immunoblotted with anti-Tyr(P), anti-p85, anti-Grb2, and
anti-LAX antibodies. As shown in Fig.
6A, Myc-tagged LAX-WT was
phosphorylated upon TCR stimulation. Mutation of these four tyrosines
completely abolished LAX phosphorylation. Upon stimulation, LAX-WT, but
not LAX-4YF, associated with p85 and Grb2 upon TCR cross-linking. We
also immunoprecipitated p85, Gads, and Grb2 from these lysates. The
association of LAX with these proteins was detected by blotting with an
anti-LAX antibody. Only LAX-WT was found to interact with p85, Gads,
and Grb2 after stimulation (Fig. 6B). Similar results were
obtained using Daudi cells (not shown). The interaction of Grb2 with
endogenous LAX could be detected in both Jurkat and Daudi cells after
anti-TCR or anti-BCR stimulation (Fig. 6C). We also examined
whether LAX interacts with other SH2 domain containing proteins, such
as PLC LAX Functions Differently from LAT--
TCR cross-linking leads to
activation of NFAT and AP-1, two critical transcription factors in
TCR-induced IL-2 production. Previous studies showed that LAT is
required for TCR-mediated activation of NFAT and AP-1 (9, 19). Because
LAX shares some similar features as LAT, such as binding of Grb2, Gads,
and p85, we next examined whether LAX could play a similar role in T
cell activation as LAT. LAT-deficient Jurkat cells (ANJ3) were
transiently transfected with a plasmid with LAT-WT, a mutant LAT with
mutation of 10 tyrosines, or a plasmid with LAX-WT together with a
luciferase reporter construct driven by a synthetic promoter containing
three copies of NFAT/AP-1-binding sites and the IL-2 minimal promoter. Sixteen to twenty four hours after transfection, these transfected cells were activated with anti-CD3 Overexpression of LAX Inhibits TCR-mediated T Cell
Activation--
To examine the role of LAX in TCR-mediated signaling,
we transiently transfected wild-type Jurkat cells with an empty
plasmid, a plasmid with LAX-WT, or a plasmid with LAX-4YF together with an NFAT/AP-1 luciferase reporter plasmid. As shown in Fig.
7B, overexpression of LAX-WT inhibited NFAT-mediated
transcription in a dose-dependent manner. Maximal
inhibition was achieved when 10 µg of plasmid was used. However,
overexpression of the LAX-4YF mutant had no inhibitory effect on
NFAT/AP-1 activation, suggesting that these tyrosine residues are
required in LAX-mediated inhibition. We also transfected Jurkat cells
with these plasmids and an AP-1 luciferase construct. Overexpression of
LAX-WT also inhibited AP-1-mediated transcription in a
dose-dependent manner, and the LAT-4YF mutant failed to
inhibit AP-1 activation (Fig. 7C).
To determine the biochemical basis for LAX-mediated inhibition, we
transfected Jurkat cells with plasmids expressing LAX-WT and LAX-4YF to
establish stable cell lines. Total lysates from these cells were
analyzed by an anti-LAX Western blot. As shown in Fig.
8C, LAX-WT and LAX-4YF
proteins were overexpressed in these stable cell lines in comparison
with LAX in untransfected Jurkat cells. Similar amounts of protein were
loaded on SDS-PAGE as indicated by an anti-PLC-
Next, we determined whether overexpression of LAX affects TCR-mediated
MAPK activation. These stable transfectants and non-transfected Jurkat
cells were stimulated with antibodies against TCR and CD28 for 5, 10, and 15 min or left untreated. Total lysates from these cells were
resolved on SDS-PAGE and analyzed by Western blotting with antibodies
against the active form of Erk, Jnk, or p38, respectively. As shown in
Fig. 8C, TCR-mediated Erk and Jnk activations were not
affected by overexpression of LAX-WT or LAX-4YF. However, in contrast
to Erk and Jnk, TCR-mediated p38 MAPK activation was strongly
suppressed in Jurkat cells overexpressing LAX-WT and not LAX-4YF.
Although how LAX functions in T cell activation remains to be
determined, our data clearly indicated that in contrast to LAT, LAX
functions to negatively regulate T cell activation by inhibiting
TCR-mediated p38 MAPK activation. Our data also suggested that p38 MAPK
activation is required for TCR-mediated AP-1/NFAT transcriptional
activation in agreement with the previous finding (29, 30) that the p38
MAPK inhibitor, SB203580, inhibits the transcriptional activation of
the IL-2 promoter.
Accumulating evidence indicates that adaptor proteins are
important in antigen receptor-mediated signaling pathways. In this paper, we report identification of a novel membrane-associated adaptor
molecule, LAX. LAX was exclusively expressed in lymphoid tissues. Of
the several cell lines we tested, LAX was found in B, T, NK, and
monocyte cell lines. In the cytoplasmic domain of LAX, there are
multiple tyrosines. These tyrosines are within the Grb2- or p85-binding
motifs. Upon stimulation via the TCR or BCR, LAX was
tyrosine-phosphorylated and interacted with Grb2, Gads, and p85. By
coexpressing LAX with Src and/or Syk tyrosine kinases, we showed that
LAX could be phosphorylated by Lck, Syk, and ZAP-70. Phosphorylation of
LAX was reduced in ZAP-70-deficient cells and was abolished in
Lck-deficient cells. By overexpressing wild-type LAX and a mutant LAX
with mutations at four critical tyrosines, we showed that
overexpression of wild-type LAX inhibited p38 MAPK activation and
NFAT/AP-1-mediated transcription in Jurkat cells, whereas
overexpression of the mutant LAX had no effect. Our data indicated that
LAX is an adaptor molecule that potentially functions to negatively
regulate TCR signaling.
LAX and LAT are membrane-associated adaptor proteins. Both of them have
a short extracellular domain, a transmembrane domain, and a cytoplasmic
domain. Whereas LAT is expressed in T cells, NK cells, mast cells, and
platelets (31), LAX is expressed in T cells, B cells, NK cells, and
monocytes. We have not tested whether LAX is present in mast cells,
platelets, or other cell types. Although LAT and LAX have no overall
homology in amino acid sequences, the tyrosine motifs in their
cytoplasmic domains are very similar (Fig. 1B). These motifs
are responsible for binding the SH2 domain-containing proteins. LAX has
five Grb2-binding motifs (YXN) in its cytoplasmic tail. It
also has a Gads motif (YVNV) identical to those in LAT. In addition,
LAX has a p85-binding motif (YXXM), which is not present in
LAT, although LAT is able to associate with p85. Upon antigen receptor
stimulation, LAX also interacted with Grb2, Gads, and p85 like LAT.
However, we have not been able to detect any significant interaction
between LAX and PLC- Overexpression of LAX-WT inhibited NFAT activation, whereas
overexpression of a LAX mutant with mutations at four tyrosines had no
effect. It is possible that overexpression of LAX could sequester other
signaling proteins from LAT and further inhibit TCR-mediated signaling.
Biochemical analysis of Jurkat cells stably transfected with WT-LAX and
LAX-4YF showed that overexpression of LAX had no significant effect on
tyrosine phosphorylation of proteins, Ca2+, Erk, or Jnk
activation, suggesting that overexpression of LAX did not inhibit
LAT-mediated signaling by sequestering Grb2, Gads, and p85 from LAT.
Interestingly, overexpression of LAX specifically inhibited
TCR-mediated p38 MAPK activation. This suggested that LAX likely
functions in the pathway of p38 MAPK.
Erk, Jnk, and p38 MAPKs are three subgroups of the MAPK superfamily.
These three kinases are all activated following T cell activation.
These MAPKs phosphorylate different subsets of substrates (32). The
substrates for p38 MAPK include transcription factors (Elk-1, ATF2,
CHOP, MEF2C, and SAP-1) and downstream protein kinases (Mnk1, Mnk2,
PRAK, MSK1, etc). It is not clear how p38 MAPK activation is coupled to
TCR engagement and how p38 contributes to IL-2 production in T cells.
Pretreatment of Jurkat cells with a specific p38 MAPK inhibitor,
SB203580, or expression of a dominant negative form of MKK6, one of the
upstream kinase of p38, can suppress the transcriptional activation of
the IL-2 promoter (29). It has been shown in mice that p38 MAPK
activation can modulate T cell development and is required for the
activation of Th1 cells but not for activation of Th2 cells (32, 33).
Our data placed LAX in the p38 pathway. However, how LAX suppresses p38
activation remains to be determined. Because the LAX mutant with
mutations of four tyrosine residues failed to inhibit p38 activation,
the interaction between LAX with Grb2, Gads, or p85 might be required
for LAX function. It is likely that LAX might recruit a negative
regulator, such as phosphatase, to the membrane to turn off p38 MAPK
activation. However, we have not been able to detect any interaction
between LAX and phosphatases.
Previous studies (9, 19) showed that LAT is critical in T cell
activation. LAT-deficient cells are defective in TCR-mediated Ras-MAPK
activation and Ca2+ flux. Our data here suggested that LAX
functions differently from LAT as follows. 1) In contrast to LAT, LAX
is not localized in lipid rafts. 2) Defective signaling in
LAT-deficient Jurkat cells could not be rescued by expression of LAX.
3) LAX does not interact with PLC- Signaling via the BCR shares many similar features as signaling via the
TCR. BLNK associates with Grb2, Vav, PLC- In summary, we identified a novel membrane-associated adaptor protein,
and we showed that it functions to negatively regulate TCR signaling.
This inhibitory signal delivered by LAX may be critical for terminating
IL-2 production in the late stage of immune responses. Interestingly,
consistent with this notion, the amount of LAX protein extracted by
Brij detergent was increased dramatically upon stimulation of Jurkat
cells with anti-TCR antibody or
PMA.2 Increased LAX protein
at the membrane might bring more inhibitory molecules to the membrane
to turn off a T cell response. The mechanism by which LAX inhibited p38
MAPK and NFAT/AP-1 transcriptional activation remains to be determined.
The precise function of LAX in lymphocyte signaling and immune response
will be revealed by analysis of LAX-deficient mice.
We thank Drs. Arthur Weiss and Robert
Abraham for kindly providing deficient Jurkat cell lines and
Dr. Mike Cook for fluorescence-activated cell sorter analysis.
*
This work was supported by National Institutes of Health
Grant 1R01 AI48674-01.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY090784 and AY090785.
Published, JBC Papers in Press, September 30, 2002, DOI 10.1074/jbc.M208946200
2
M. Zhu, E. Janssen, K. Leung, and W. Zhang, unpublished data.
The abbreviations used are:
BCR, B cell
receptor;
TCR, T cell receptor;
ITAMs, immunoreceptor tyrosine-based
activation motifs;
MAPK, mitogen-activated protein kinase;
PLC, phospholipase C;
PI-3 kinase, phosphatidylinositol 3-kinase;
ITAM, immunoreceptor tyrosine-based activation motifs;
IL, interleukin;
PMA, phorbol 12-myristate 13-acetate;
WT, wild type;
G3PDH, glyceraldehyde-3-phosphate dehydrogenase;
SH, Src homology;
GST, glutathione S-transferase;
JNK, c-Jun N-terminal kinase;
Erk, extracellular signal-regulated kinase;
NFAT, nuclear factor of
activated T cells;
TK, thymidine kinase.
Molecular Cloning of a Novel Gene Encoding a
Membrane-associated Adaptor Protein (LAX) in Lymphocyte Signaling*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 (16). The binding of Grb2 to
LAT is postulated to recruit Sos to the membrane to activate Ras. The
association of LAT with PLC-
1 recruits PLC-
1 to the membrane so
it can be phosphorylated and activated. Activation of PLC-
1 is
essential for TCR-mediated Ca2+ flux and activation of
Ras-GRP, a molecule that functions to activate Ras (17, 18).
TCR-mediated Ras-MAPK activation and Ca2+ flux are
defective in LAT-deficient Jurkat cells, indicating that LAT is
essential for TCR-mediated signaling (9, 19). Binding of Gads to LAT
recruits SLP-76 indirectly to the membrane (20, 21). SLP-76 is also
essential in TCR-mediated signaling as indicated in SLP-76-deficient
cells (11, 22). TCR-mediated MAPK activation and Ca2+ flux
are severely compromised in these cells.
2 activation and Ca2+ flux are
defective in BLNK-deficient cells (24). BCR-mediated JNK and Erk
activation are also compromised. However, in contrast to LAT, BLNK is
not constitutively localized to the membrane. Furthermore, LAT
deficiency in Jurkat cells cannot be complemented by BLNK (25).
Therefore, it is less likely that BLNK functions as both LAT and SLP-76
in B cells. It is possible that B cells or other lymphoid cells use a
LAT-like molecule to link the receptor engagement to Ras-MAPK
activation and Ca2+ flux. Due to the near completion of the
human genome sequencing, it might be possible to find a LAT homolog in
the human genome data base.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 monoclonal antibodies from Upstate Biotechnology, Inc.; anti-phospho-JNK MAPK,
anti-phospho-p44/42 MAPK, anti-phospho-p38 MAPK, and anti-p38 MAPK
antisera from Cell Signaling Technology, Inc.
(C305, 1:50 dilution) for Jurkat cells or
goat anti-human IgM F(ab')2 for Daudi cells for 1.5 min, left
untreated, or, as indicated in the figures, lysed in 1% Brij lysis
buffer with different protease inhibitors and phosphatase inhibitors.
Postnuclear fractions were used in immunoprecipitation with different
antibodies as indicated in each figure. Separation of the cytosolic
fraction and membrane fraction was performed using Dounce
homogenization and ultracentrifugation. Purification of lipid rafts was
done using a sucrose gradient (27).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 and consequently LAT function (16). Tyr-171 and Tyr-191 are
both within a YVNV sequence context. In addition to these tyrosine
motifs, we also searched for novel proteins containing a transmembrane domain.

View larger version (35K):
[in a new window]
Fig. 1.
The deduced amino acid sequence and tyrosine
motifs of LAX. A, comparison of human and mouse LAX
proteins. The LAX gene was initially identified by BLAST
searching the human genome. A LAX cDNA was amplified
from a Jurkat cDNA library and sequenced. The mouse LAX
cDNA was amplified from mouse spleen and sequenced. Human and mouse
LAX proteins were aligned using the Pairwise Blast program from NCBI. A
potential transmembrane domain is underlined. Conserved
tyrosine residues are highlighted. B,
comparison of tyrosine motifs in the cytoplasmic domains of LAX and
LAT. The GenBankTM accession number for human
LAX is AY090784, and the accession number for mouse
LAX is AY090785.

View larger version (53K):
[in a new window]
Fig. 2.
Expression of LAX in different human tissues
and cell lines. cDNAs from various human tissues and cell
lines were used in a PCR to amplify a LAX cDNA fragment using
LAX-specific primers. Two primers for the G3PDH gene were
also included in the PCR to amplify the G3PDH gene as a
control for the amount of cDNA used in each PCR.
PBL, peripheral blood leukocyte.

View larger version (20K):
[in a new window]
Fig. 3.
Membrane localization of LAX. A,
cytosolic and membrane fractions were prepared by Dounce homogenization
in a hypotonic buffer and subsequent ultracentrifugation. Membrane
fractions were further extracted by 1% Brij97 lysis buffer. For
detection of LAT and ZAP-70, samples from the cytosolic and membrane
fractions were resolved using SDS-PAGE and immunoblotted with anti-LAT
and anti-ZAP-70 antibodies. For detection of LAX, lysates from both
fractions were subjected to anti-LAX immunoprecipitation using rabbit
anti-LAX antiserum. Anti-LAX immunoprecipitates were resolved using
SDS-PAGE and blotted with anti-LAX monoclonal antibody. HC
indicates heavy chain from the antibody for immunoprecipitation
(IP). B, lipid rafts and Triton-soluble fractions
were isolated using sucrose gradients as described previously
(27). Most proteins in lipid rafts were present in
fraction 3. Fractions 8-12 were Triton-soluble.
Lipid rafts were further solubilized with 1% Brij and 30 mM octyl-
-D-glucoside before being subjected
to anti-LAX immunoprecipitation. The presence of LAX was detected by
anti-LAX immunoblotting.
antibody (C305) and Daudi cells were stimulated with goat anti-human IgM F(ab')2 for 0, 1.5, 5, 10, and 20 min before lysis.
These lysates were then subjected to immunoprecipitation with rabbit anti-LAX antiserum. Immunoprecipitated proteins were resolved on
SDS-PAGE and blotted with anti-phosphotyrosine and anti-LAX antibodies.
As shown in Fig. 4, A and
B, LAX was rapidly tyrosine-phosphorylated upon stimulation
with anti-TCR or anti-BCR antibodies. An equal amount of LAX protein
was precipitated under each condition. Tyrosine phosphorylation of LAX
peaked at 1.5 min, which is very similar to that of LAT (data not
shown). It appeared that LAX was dephosphorylated more rapidly in
Jurkat cells than in Daudi cells. We also observed a 135-kDa
phosphorylated protein associated with LAX in Daudi cells.

View larger version (38K):
[in a new window]
Fig. 4.
LAX is tyrosine-phosphorylated upon
stimulation via the antigen receptor. A, Jurkat cells were
stimulated by an anti-TCR antibody (C305) for 0, 1.5, 5, 10, and 20 min
before lysis. B, Daudi cells were stimulated with goat
anti-human IgM F(ab')2 for 0, 1.5, 5, 10, and 20 min. LAX
was immunoprecipitated (IP) from lysates using rabbit
anti-LAX antiserum. Anti-LAX immunoprecipitates were resolved on
SDS-PAGE. Phosphorylation of LAX was detected by an anti-Tyr(P)
blot (top panel), and LAX was detected by blotting with an
anti-LAX monoclonal antibody (bottom panel). As a control,
preimmune serum was used for immunoprecipitation of lysates from Daudi
cells stimulated with goat anti-human F(ab')2 and then
blotted with anti-Tyr(P) antibody (B, top panel).
HC, immunoglobulin heavy chain; PY, Tyr(P).

View larger version (27K):
[in a new window]
Fig. 5.
LAX is a substrate of Src and Syk tyrosine
kinases. A, Myc-tagged LAX and different tyrosine kinases as
indicated were coexpressed in 293T cells. 36-48 h after transfection,
LAX was immunoprecipitated by anti-Myc antibody. Phosphorylation of LAX
was detected by anti-Tyr(P) (PY) antibody, and LAX protein
in each sample was detected by blotting with an anti-LAX monoclonal
antibody (left panels). Phosphorylation of LAT by these
kinases was performed in the same way (right panels). *
indicated the positions for LAX or LAT. B, LAX was
immunoprecipitated from unstimulated or C305-stimulated Jurkat cells
(E6.1), P116 (ZAP70-deficient), and J.CaM1.6 (Lck-deficient cells). LAX
phosphorylation in these cells was detected by an anti-phosphotyrosine
antibody.
antibody (C305), LAX was
immunoprecipitated from the stimulated and unstimulated cell lysates
and immunoblotted with anti-phosphotyrosine and anti-LAX antibodies. As
shown in Fig. 5B, compared with LAX phosphorylation in
wild-type Jurkat cells (E6.1), LAX phosphorylation was significantly reduced in ZAP-70-deficient cells (P116). There was no tyrosine phosphorylation of LAX in Lck-deficient cells (J.CaM1.6). A similar amount of LAX was immunoprecipitated from these cells as indicated by
anti-LAX blotting. Because Lck is critical for activation of ZAP-70 and
other tyrosine kinases, it was not surprising that there was no
tyrosine phosphorylation of LAX in the absence of Lck. LAX could not be
phosphorylated upon TCR cross-linking in the absence of Lck. However,
in the absence of ZAP-70, Lck, and/or other tyrosine kinases activated
by Lck could still phosphorylate LAX although at a reduced level. These
data, together with the data from coexpression in 293T cells, suggested
that LAX is a substrate of Lck and Syk family tyrosine kinases.
1, PLC-
2, Vav, SHP1, and SHP2. We failed to detect any
significant interaction between LAX and these proteins (data not
shown). Our data indicated that upon antigen receptor stimulation, LAX
could interact with Grb2, Gads, and p85 and recruit these proteins to
the membrane to activate downstream signaling pathways.

View larger version (31K):
[in a new window]
Fig. 6.
LAX interacts with Grb2, the p85 subunit of
PI-3 kinase, and Gads upon antigen receptor stimulation.
Myc-tagged wild-type LAX and mutant LAX with four mutations at Tyr-193,
Tyr-268, Tyr-294, and Tyr-373 were stably expressed in Jurkat cells.
LAX (A), p85, Grb2, and Gads (B) were
immunoprecipitated (IP) and blotted with antibodies against
LAX, p85, and Grb2 to detect specific interactions. C, Grb2
was immunoprecipitated from Jurkat and Daudi lysates followed by
blotting with an anti-LAX monoclonal antibody. WCL,
whole-cell lysate; PY, phosphotyrosine.
antibody (OKT3) or PMA + ionomycin for 6 h and lysed. Cell lysates were used to determine
luciferase activity. As shown in Fig.
7A, the defect in NFAT/AP-1
activation in LAT-deficient cells could be corrected by introducing
wild-type LAT into these cells and not the LAT-10YF mutant.
Transfection of these cells with LAX failed to restore NFAT/AP-1
activation, suggesting that LAX might play a different role in T cell
activation.

View larger version (36K):
[in a new window]
Fig. 7.
Overexpression of LAX inhibits
TCR-mediated NFAT/AP-1activation. A, LAX functions
differently from LAT. 5 µg of pNFAT-luciferase plasmid, 20 ng of
Renilla-TK luciferase plasmid, and 5 µg of LAT-WT,
LAT-10YF, or LAX-WT plasmid were used to transfect LAT-deficient Jurkat
cells by electroporation. Sixteen to twenty four hours after
transfection, transfectants were left untreated and stimulated with
OKT3 or PMA plus ionomycin for maximal activity for 6 h. Dual
luciferase activity was assayed, and NFAT-luciferase activity was
normalized by Renilla luciferase activity and represented as
the percentage of maximal activity. B, LAX-mediated
inhibition is dose-dependent. 5 µg of
pNFAT/AP-1-Luciferase plasmid, 20 ng of Renilla-TK
luciferase plasmid, and 2.5, 5, or 10 µg of WT-LAX plasmid, 10 µg
of an empty vector, or 10 µg of LAX-4YF mutant with mutations at
Tyr-193, Tyr-268, Tyr-294, and Tyr-373 were used to transfect wild-type
Jurkat cells by electroporation. The assay of luciferase activity was
done similarly as in A. C, AP-1-mediated
transcription is inhibited by overexpression of LAX. This experiment
was performed similarly as in B except that an
AP-1-luciferase reporter construct was used. All experiments were
performed in triplicate and are presented as the means ± S.D.
1 blot (Fig.
8C). Overexpression of either WT or mutant LAX had no
significant effect on TCR-mediated tyrosine phosphorylation of cellular
proteins (Fig. 8A) and TCR-mediated Ca2+ flux
(Fig. 8B). We also determined the effect of overexpression of LAX on TCR-mediated Ca2+ flux by cotransfection with a
plasmid expressing green fluorescent protein (GFP) in a transient
transfection assay. We did not observe any difference of
Ca2+ flux in GFP+ cells that likely
overexpressed LAX protein (data not shown). These data suggested that
LAX is not likely involved in TCR-mediated Ca2+
mobilization.

View larger version (34K):
[in a new window]
Fig. 8.
Overexpression of LAX selectively inhibits
TCR-mediated p38 MAPK activation. A, Jurkat cells and
transfectants that expressed either LAX-WT or LAX-4YF were stimulated
with an anti-TCR antibody (C305) for 1.5 min before lysis.
Post-nuclear lysates were analyze by Western blotting with an
anti-Tyr(P) antibody. B, Ca2+ flux in
Jurkat cells and stable transfectants that expressed either LAX-WT or
LAX-4YF. C, Jurkat cells and stable transfectants were
stimulated with anti-TCR plus anti-CD28 antibodies for 0, 5, 10, and 15 min. Activation of p38, JNK, and Erk MAPK were detected by Western
blotting with anti-phospho-p38 MAPK, anti-phospho-JNK, and
anti-phospho-Erk antibodies. The expression level of LAX was detected
by blotting with an anti-LAX antibody. The same membrane was blotted
with an anti-PLC
1 antibody for equal protein loading. The stable
transfectant clones shown in A-C are representative of
three independent clones that expressed either LAX-WT or LAX-4YF.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1/2.
1 or -
2. Thus, LAX is less
likely to function in linking receptor engagement to Ca2+ flux.
1, and Nck in B cells
similar to LAT and SLP-76 in T cells. BLNK is not constitutively localized in the membrane, which is different from LAT. Therefore, there might exist a LAT-like molecule in B cells. This molecule functions to recruit BLNK and its associated proteins to the membrane. As opposed to LAT, LAX is expressed in B cells. Upon activation via the
BCR, LAX became tyrosine-phosphorylated. We have attempted to perform
similar experiments to determine whether overexpression of LAX affects
BCR-mediated NFAT activation. We failed to obtain any conclusive
results due to a low efficiency of transfection with these B cells. The
function of LAX in B cells needs to be further studied. Because LAX is
not localized in lipid rafts and does not associate with PLC-
1/2, it
is less likely that LAX functions like LAT in B cells.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of Immunology,
Rm. 112, Jones Bldg., Box 3010, Duke University Medical Center, Durham,
NC 27710. Tel.: 919-613-7803; Fax: 919-684-8982; E-mail: zhang033@mc.duke.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Reth, M.
(1989)
Nature
338,
383-384[Medline]
[Order article via Infotrieve]
2.
Chan, A. C.,
Iwashima, M.,
Turck, C. W.,
and Weiss, A.
(1992)
Cell
71,
649-662[CrossRef][Medline]
[Order article via Infotrieve]
3.
Weiss, A.,
and Littman, D. R.
(1994)
Cell
76,
263-274[CrossRef][Medline]
[Order article via Infotrieve]
4.
Chan, A. C.,
and Shaw, A. S.
(1996)
Curr. Opin. Immunol.
8,
394-401[CrossRef][Medline]
[Order article via Infotrieve]
5.
Wange, R. L.,
and Samelson, L. E.
(1996)
Immunity
5,
197-205[CrossRef][Medline]
[Order article via Infotrieve]
6.
Clements, J. L.,
Boerth, N. J.,
Lee, J. R.,
and Koretzky, G. A.
(1999)
Annu. Rev. Immunol.
17,
89-108[CrossRef][Medline]
[Order article via Infotrieve]
7.
Kurosaki, T.
(2000)
Curr. Opin. Immunol.
12,
276-281[CrossRef][Medline]
[Order article via Infotrieve]
8.
Tamir, I.,
and Cambier, J. C.
(1998)
Oncogene
17,
1353-1364[CrossRef][Medline]
[Order article via Infotrieve]
9.
Finco, T. S.,
Kadlecek, T.,
Zhang, W.,
Samelson, L. E.,
and Weiss, A.
(1998)
Immunity
9,
617-626[CrossRef][Medline]
[Order article via Infotrieve]
10.
Kelly, M. E.,
and Chan, A. C.
(2000)
Curr. Opin. Immunol.
12,
267-275[CrossRef][Medline]
[Order article via Infotrieve]
11.
Yablonski, D.,
Kuhne, M. R.,
Kadlecek, T.,
and Weiss, A.
(1998)
Science
281,
413-416 12.
Zhang, W.,
and Samelson, L. E.
(2000)
Semin. Immunol.
12,
35-41[CrossRef][Medline]
[Order article via Infotrieve]
13.
Rudd, C. E.
(1999)
Cell
96,
5-8[CrossRef][Medline]
[Order article via Infotrieve]
14.
Jackman, J. K.,
Motto, D. G.,
Sun, Q.,
Tanemoto, M.,
Turck, C. W.,
Peltz, G. A.,
Koretzky, G. A.,
and Findell, P. R.
(1995)
J. Biol. Chem.
270,
7029-7032 15.
Boerth, N. J.,
Sadler, J. J.,
Bauer, D. E.,
Clements, J. L.,
Gheith, S. M.,
and Koretzky, G. A.
(2000)
J. Exp. Med.
192,
1047-1058 16.
Zhang, W.,
Sloan-Lancaster, J.,
Kitchen, J.,
Trible, R. P.,
and Samelson, L. E.
(1998)
Cell
92,
83-92[CrossRef][Medline]
[Order article via Infotrieve]
17.
Ebinu, J. O.,
Bottorff, D. A.,
Chan, E. Y.,
Stang, S. L.,
Dunn, R. J.,
and Stone, J. C.
(1998)
Science
280,
1082-1086 18.
Ebinu, J. O.,
Stang, S. L.,
Teixeira, C.,
Bottorff, D. A.,
Hooton, J.,
Blumberg, P. M.,
Barry, M.,
Bleakley, R. C.,
Ostergaard, H. L.,
and Stone, J. C.
(2000)
Blood
95,
3199-3203 19.
Zhang, W.,
Irvin, B. J.,
Trible, R. P.,
Abraham, R. T.,
and Samelson, L. E.
(1999)
Int. Immunol.
11,
943-950 20.
Liu, S. K.,
Fang, N.,
Koretzky, G. A.,
and McGlade, C. J.
(1999)
Curr. Biol.
9,
67-75[CrossRef][Medline]
[Order article via Infotrieve]
21.
Yoder, J.,
Pham, C.,
Iizuka, Y. M.,
Kanagawa, O.,
Liu, S. K.,
McGlade, J.,
and Cheng, A. M.
(2001)
Science
291,
1987-1991 22.
Yablonski, D.,
Kadlecek, T.,
and Weiss, A.
(2001)
Mol. Cell. Biol.
21,
4208-4218 23.
Fu, C.,
Turck, C. W.,
Kurosaki, T.,
and Chan, A. C.
(1998)
Immunity
9,
93-103[CrossRef][Medline]
[Order article via Infotrieve]
24.
Ishiai, M.,
Kurosaki, M.,
Pappu, R.,
Okawa, K.,
Ronko, I., Fu, C.,
Shibata, M.,
Iwamatsu, A.,
Chan, A. C.,
and Kurosaki, T.
(1999)
Immunity
10,
117-125[CrossRef][Medline]
[Order article via Infotrieve]
25.
Wong, J.,
Ishiai, M.,
Kurosaki, T.,
and Chan, A. C.
(2000)
J. Biol. Chem.
275,
33116-33122 26.
Straus, D. B.,
and Weiss, A.
(1992)
Cell
70,
585-593[CrossRef][Medline]
[Order article via Infotrieve]
27.
Zhang, W.,
Trible, R. P.,
and Samelson, L. E.
(1998)
Immunity
9,
239-246[CrossRef][Medline]
[Order article via Infotrieve]
28.
Williams, B. L.,
Schreiber, K. L.,
Zhang, W.,
Wange, R. L.,
Samelson, L. E.,
Leibson, P. J.,
and Abraham, R. T.
(1998)
Mol. Cell. Biol.
18,
1388-1399 29.
Matsuda, S.,
Moriguchi, T.,
Koyasu, S.,
and Nishida, E.
(1998)
J. Biol. Chem.
273,
12378-12382 30.
Zhang, J.,
Salojin, K. V.,
Gao, J. X.,
Cameron, M. J.,
Bergerot, I.,
and Delovitch, T. L.
(1999)
J. Immunol.
162,
3819-3829 31.
Facchetti, F.,
Chan, J. K.,
Zhang, W.,
Tironi, A.,
Chilosi, M.,
Parolini, S.,
Notarangelo, L. D.,
and Samelson, L. E.
(1999)
Am. J. Pathol.
154,
1037-1046 32.
Rincon, M.,
Flavell, R. A.,
and Davis, R. A.
(2000)
Free Radic. Biol. Med.
28,
1328-1337[CrossRef][Medline]
[Order article via Infotrieve]
33.
Mulroy, T.,
and Sen, J.
(2001)
Eur. J. Immunol.
31,
3056-3063[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. J. Shapiro, C. T. Nguyen, H. Aghajanian, W. Zhang, and V. S. Shapiro Negative Regulation of TCR Signaling by Linker for Activation of X Cells via Phosphotyrosine-Dependent and -Independent Mechanisms J. Immunol., November 15, 2008; 181(10): 7055 - 7061. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu and W. Zhang Identification of a new transmembrane adaptor protein that constitutively binds Grb2 in B cells J. Leukoc. Biol., September 1, 2008; 84(3): 842 - 851. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sancho-Shimizu, R. Khan, S. Mostowy, L. Lariviere, R. Wilkinson, N. Riendeau, M. Behr, and D. Malo Molecular Genetic Analysis of Two Loci (Ity2 and Ity3) Involved in the Host Response to Infection With Salmonella Typhimurium Using Congenic Mice and Expression Profiling Genetics, October 1, 2007; 177(2): 1125 - 1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Mutch, R. Sanyal, T. L. Unruh, L. Grigoriou, M. Zhu, W. Zhang, and J. P. Deans Activation-induced endocytosis of the raft-associated transmembrane adaptor protein LAB/NTAL in B lymphocytes: evidence for a role in internalization of the B cell receptor Int. Immunol., January 1, 2007; 19(1): 19 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dong, B. Corre, E. Foulon, E. Dufour, A. Veillette, O. Acuto, and F. Michel T cell receptor for antigen induces linker for activation of T cell-dependent activation of a negative signaling complex involving Dok-2, SHIP-1, and Grb-2 J. Exp. Med., October 30, 2006; 203(11): 2509 - 2518. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Perchonock, M. C. Fernando, W. J. Quinn III, C. T. Nguyen, J. Sun, M. J. Shapiro, and V. S. Shapiro Negative Regulation of Interleukin-2 and p38 Mitogen-Activated Protein Kinase during T-Cell Activation by the Adaptor ALX. Mol. Cell. Biol., August 1, 2006; 26(16): 6005 - 6015. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhu, I. Rhee, Y. Liu, and W. Zhang Negative Regulation of Fc{epsilon}RI-mediated Signaling and Mast Cell Function by the Adaptor Protein LAX J. Biol. Chem., July 7, 2006; 281(27): 18408 - 18413. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Kolsch, B. Arndt, D. Reinhold, J. A. Lindquist, N. Juling, S. Kliche, K. Pfeffer, E. Bruyns, B. Schraven, and L. Simeoni Normal T-Cell Development and Immune Functions in TRIM-Deficient Mice.< |